Johnson & Johnson gets FDA approval for schizophrenia drug

12/8/2003 | NYTimes.com

Drugmaker Johnson & Johnson announced it has received FDA approval for its schizophrenia drug, Risperdal, to treat bipolar I disorder, the most severe form of the disease. The company said users of the drug showed significant improvement over persons treated in a control group.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC